Author

A. E. Hale

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 2 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:host-pathogen & immune response· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Approach:genetic perturbation / CRISPR· 1

Frequent Co-Authors

N. J. Moorman· 2 shared B. E. Weissman· 1 shared B. M. Bowman· 1 shared B. S. Graham· 1 shared B. Yount· 1 shared D. Collins-McMillen· 1 shared D. Goldfarb· 1 shared E. M. Lenarcic· 1 shared

Activity by Year

2019-2020 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 15 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersMicrobiology

N. J. Moorman

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

FOXO Transcription Factors Activate Alternative Major Immediate Early Promoters to Induce Human Cytomegalovirus Reactivation

A. E. Hale, D. Collins-McMillen, E. M. Lenarcic, J. P. Kamil, F. Goodrum, N. J. Moorman

This study identifies FOXO transcription factors as critical for activating alternative MIE promoters during HCMV reactivation from latency in hematopoietic progenitor cells.

Proceedings of the National Academy of Sciences · Jul 21, 2020Peer-reviewedMicrobiology

Gain-of-function genetic screen of the kinome reveals BRSK2 as an inhibitor of the NRF2 transcription factor

T. Y. Tamir, B. M. Bowman, M. J. Agajanian, D. Goldfarb, T. P. Schrank, T. Stohrer, A. E. Hale, P. F. Siesser, S. J. Weir, R. M. Murphy, K. M. LaPak, B. E. Weissman, N. J. Moorman, M. B. Major

The paper identifies BRSK2 as a negative regulator of NRF2 by inhibiting protein synthesis through mTOR downregulation, suggesting it as a potential therapeutic target for NRF2-related diseases.

bioRxiv · Nov 5, 2019Cell Biology

Trypsin treatment unlocks barrier for zoonotic coronaviruses infection

V. D. Menachery, K. Dinnon, B. Yount, E. T. McAnarney, L. Gralinski, A. E. Hale, R. Graham, T. D. Scobey, S. J. Anthony, L. Wang, B. S. Graham, S. H. Randell, W. I. Lipkin, R. S. Baric

This study shows that proteolytic cleavage, not receptor binding, is the main barrier for two MERS-like bat coronaviruses to infect human cells, and that trypsin treatment can overcome this barrier.

bioRxiv · Sep 16, 2019Microbiology